Posted by Michael Wonder on 30 Jul 2025
Calidi Biotherapeutics receives FDA fast track designation for CLD-201 (SuperNova), a first in class stem cell loaded viral therapy for the treatment of patients with soft tissue sarcoma
29 July 2025 - Calidi Biotherapeutics today announced that it received fast track designation from the US FDA for CLD-201 (SuperNova), the company’s allogeneic adipose stem-cell loaded oncolytic virus for the treatment of soft tissue sarcoma.
CLD-201 is comprised of adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus, for the treatment of patients with advanced solid tumours including sarcoma, triple-negative breast cancer, and head and neck squamous cell carcinoma.
